Cited by 233Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and TreatmentsProtein Kinase Regulation and GTPase Signaling

The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis

Open access
Knipe, Rachel S., Tager, Andrew M., Liao, James K.·2015·Pharmacological Reviews

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive lung scarring, short median survival, and limited therapeutic options, creating great need for new pharmacologic therapies. IPF is thought to result from repetitive environmental injury to the lung epithelium, in the context of aberrant host wound healing responses. Tissue responses to injury fundamentally involve reorganization of the actin cytoskeleton of participating cells, including epithelial cells, fibroblasts, endothelial cells, and macrophages. Actin filament assembly and actomyosin contraction are directed by the Rho-associated coiled-coil forming protein kinase (ROCK) family of serine/threonine kinases (ROCK1 and ROCK2). As would therefore be expected, lung ROCK activation has been demonstrated in humans with IPF and in animal models of this disease. ROCK inhibitors can prevent fibrosis in these models, and more importantly, induce the regression of already established fibrosis. Here we review ROCK structure and function, upstream activators and downstream targets of ROCKs in pulmonary fibrosis, contributions of ROCKs to profibrotic cellular responses to lung injury, ROCK inhibitors and their efficacy in animal models of pulmonary fibrosis, and potential toxicities of ROCK inhibitors in humans, as well as involvement of ROCKs in fibrosis in other organs. As we discuss, ROCK activation is required for multiple profibrotic responses, in the lung and multiple other organs, suggesting ROCK participation in fundamental pathways that contribute to the pathogenesis of a broad array of fibrotic diseases. Multiple lines of evidence therefore indicate that ROCK inhibition has great potential to be a powerful therapeutic tool in the treatment of fibrosis, both in the lung and beyond.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/pr.114.009381

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Knipe, R. S., Tager, A. M., & Liao, J. K.
Affiliations
Harvard University (US)
Venue
Pharmacological Reviews
Publisher
Elsevier BV
Published
2015-01
Volume
67
Issue
1
Pages
103-117
ISSN
0031-6997 (ISSN-L)
OpenAlex
W2155116729
Cited by
233
References
150
Citations by year
2026: 19 · 2025: 24 · 2024: 24 · 2023: 25 · 2022: 19 · 2021: 28 · 2020: 21 · 2019: 13 · 2018: 20 · 2017: 21 · 2016: 14 · 2015: 4
FWCI
2.22
Type
journal article
Language
en
Open access
Locations
  • Pharmacological Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Scleroderma Research Foundation
  • National Institutes of Health (UL1TR000430)
  • National Heart, Lung, and Blood Institute (HL095732, HL-108975, HL-052233, R01HL095732, R01HL091933, R01HL108975, R01HL052233, T32HL116275)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK085006)
  • National Institute of Neurological Disorders and Stroke (R01NS070001)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR007258)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
Rho kinase, ROCK1, ROCK2, idiopathic pulmonary fibrosis, pulmonary fibrosis, ROCK inhibitor, profibrotic signaling, actin cytoskeleton, lung injury, wound healing, fibrosis regression, fibrotic diseases
MeSH terms
Animals, Disease Models, Animal, Humans, Lung, Protein Conformation, Structure-Activity Relationship, Drug Design, Signal Transduction, Protein Kinase Inhibitors, rho-Associated Kinases, Idiopathic Pulmonary Fibrosis, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review